Acute Effects of R- and S-MDMA in Healthy Subjects

Phase 1 Completed 24 enrolled University Hospital, Basel, Switzerland

RandomizedCrossoverTriple-blindBasic science

Summary

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA is currently investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Timeline

Start: 2022-10-01
Primary completion: 2024-01-13
Completion: 2024-01-13

Publications

Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, Luethi D, Liechti ME. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology. 2024 Dec;50(2):362-371. doi: 10.1038/s41386-024-01972-6. Epub 2024 Aug 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midomafetamine	Unknown	125 mg	—
Subject	R-3,4-methylenedioxymethamphetamine	Unknown	125 mg	—
Subject	R-3,4-methylenedioxymethamphetamine	Unknown	250 mg	—
Subject	S-3,4-methylenedioxymethamphetamine	Unknown	125 mg	—

Indications

No indication recorded.